Perspective Therapeutics, INC 10-Q quarterly reports

Perspective Therapeutics reports significant progress in its radiopharmaceutical pipeline, with strong cash reserves extending funding into late 2027, alongside a substantial capital raise.

Perspective Therapeutics reported increased net losses in Q3 2025 due to significant investments in radiopharmaceutical R&D and manufacturing, while advancing multiple clinical programs.

Perspective Therapeutics reported a significant increase in net loss for Q2 2025, driven by expanded research and development activities for its radiopharmaceutical pipeline, while maintaining strong liquidity into late 2026.

Perspective Therapeutics reports its financial results for the first quarter of 2025, showcasing progress in its clinical trials and pipeline development.

Perspective Therapeutics' Q3 2024 filing reveals significant financial growth and strategic advancements in its alpha therapy programs, alongside the divestiture of its brachytherapy business.

Perspective Therapeutics reports a significant increase in cash reserves and advancements in its clinical trials for targeted alpha therapies in its Q2 2024 report.

Perspective Therapeutics reports a net loss for Q1 2024 but secures substantial funding through multiple agreements and a public offering, positioning the company for future growth.